OutlookThe Company has updated its anticipated full year 2012 net sales to be in the range of $476 million to $485 million, as compared with the previously announced guidance of $472 million to $489 million, and has updated its as-adjusted earnings per share excluding stock-based compensation guidance to be in the range of $0.32 to $0.36 per diluted share from the previously communicated range of $0.26 to $0.36. The Company's earnings target excludes non-compete and transition costs associated with converting a major portion of independent foot and ankle territories to direct, costs associated with the previously announced restructuring, possible future acquisitions, other material future business developments, non-cash stock-based compensation expense, and costs associated with the Company's DPA (including the associated independent monitor).
Wright Medical Group, Inc. Reports 2012 Second Quarter Financial Results
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts